Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology
Reference43 articles.
1. Yadav MP, Singla S, Thakral P et al (2016) Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed/refractory non-Hodgkin’s lymphoma. Nucl Med Commun 37:735–742
2. Bhusari P, Vatsa R, Singh G et al (2017) Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients. Int J Cancer 140:938–947
3. Srichandan T, Nautiyal A, Jha A et al (2022) Comparison of pre therapeutic and post therapeutic dosimetry with 177Lu-Trastuzumab in patients with HER-2 positive metastatic breast cancer. J Nucl Med 63
4. Menon SR, Mitra A, Chakraborty A et al (2022) Clinical dose preparation of [177Lu]Lu-DOTA-Pertuzumab using medium specific activity [177Lu]LuCl3 for radioimmunotherapy of breast and epithelial ovarian cancers, with HER2 receptor overexpression. Cancer Biother Radiopharm 37:384–402
5. Banerjee S, Pillai MRA, Knapp FF (2015) Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. Chem Rev 115:2934–2974
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献